Evaluation of MRI features of neuromas in oncological amputees, and the relation to pain
- PMID: 39264418
- DOI: 10.1007/s00256-024-04779-0
Evaluation of MRI features of neuromas in oncological amputees, and the relation to pain
Abstract
Objective: The impact of time on neuroma growth and morphology on pain intensity is unknown. This study aims to assess magnetic resonance imaging (MRI) differences between symptomatic and non-symptomatic neuromas in oncological amputees, and whether time influences MRI-detected neuroma dimensions and their association with pain.
Material and methods: Oncological patients who underwent traditional extremity amputation were included. Post-amputation MRIs were assessed before decision for neuroma surgery. Chart review was performed for residual limb pain (numeric rating scale, 0-10) and the presence of neuropathic symptoms. Neuromas were classified as symptomatic or non-symptomatic, with neuroma size expressed as radiological neuroma-to-nerve-ratio (NNR).
Results: Among 78 neuromas in 60 patients, the median NNR was 2.0, and 56 neuromas (71.8%) were symptomatic with a median pain score of 3.5. NNR showed no association with symptomatology or pain intensity but correlated with a longer time-to-neuroma-excision interval and a smaller nerve caliber. Symptomatic neuromas were associated with lower extremity amputation, T2 heterogeneity, and the presence of heterotopic ossification. Lower extremity amputation, T2 heterogeneity, perineural edema, and presence of heterotopic ossification were associated with more painful neuromas.
Conclusion: MRI features associated with symptomatic neuromas and pain intensity were identified. Awareness of the potential clinical significance of these imaging features may help in the interpretation of MRI exams and may aid clinicians in patient selection for neuroma surgery in oncological amputees.
Keywords: Amputation; MRI; Neuroma; Neuropathic pain.
© 2024. The Author(s), under exclusive licence to International Skeletal Society (ISS).
Conflict of interest statement
Declarations. Conflict of interest: Authors EV, FR, WL, MF, EN, MJ, FS, and JH have nothing to disclose. IV is a consultant for AxoGen Inc, Checkpoint Surgical Inc, Integra Lifesciences Inc. KE is a consultant for AxoGen Inc, Checkpoint Surgical Inc, Integra Lifesciences Inc, Tulavi Therapeutics Inc, Tissium and BioCircuit.
References
-
- Evans DR, Lazarides AL, Visgauss JD, Somarelli JA, Blazer DG, Brigman BE, et al. Limb salvage versus amputation in patients with osteosarcoma of the extremities: an update in the modern era using the National Cancer Database. BMC Cancer. 2020 [cited 2022 Dec 14];20(1):1–11. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-07502-z .
-
- Tofthagen C, McMillan SC. Pain, neuropathic symptoms, and physical and mental well-being in persons with cancer. Cancer Nurs. 2010 [cited 2024 Jan 22];33(6):436–44. https://pubmed.ncbi.nlm.nih.gov/21479139/ .
-
- Cherif F, Zouari HG, Cherif W, Hadded M, Cheour M, Damak R. Depression prevalence in neuropathic pain and its impact on the quality of life. Pain Res Manag. 2020 [cited 2022 Dec 9];2020. https://pubmed-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/32617124/ .
-
- Hwang CD, Hoftiezer YAJ, Raasveld FV, et al. Biology and pathophysiology of symptomatic neuromas. Pain. 2023;65:550–64. https://doi.org/10.1097/j.pain.0000000000003055 . - DOI
-
- Oliveira KMC, Pindur L, Han Z, Bhavsar MB, Barker JH, Leppik L. Time course of traumatic neuroma development. PLoS One. 2018 [cited 2023 May 6];13(7). https://pubmed.ncbi.nlm.nih.gov/30011306/ .
MeSH terms
LinkOut - more resources
Full Text Sources
Medical